Low-dose ATG/PTCy for graft-versus-host disease prevention in haploidentical transplantation: influences of ATG doses and pre-ATG absolute lymphocyte count

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) has been administered for graft-versus-host disease (GVHD) prophylaxis of haploidentical transplantation (haplo-HSCT) in recent years. However, the optimal doses of ATG and PTCy are yet to be determined. Here, we report the joint use of low-dose ATG (7.5 or 5 mg/Kg) and PTCy (29 mg/Kg) for GVHD prophylaxis in our center and analyze the impact of different ATG doses and absolute lymphocyte count (ALC) before ATG infusion. Fifty-one consecutive leukemia patients who underwent haplo-HSCT with this regimen were included, with 27 and 24 patients receiving 7.5 and 5.0 mg/Kg ATG, respectively. The 100-day cumulative incidences (CIs) of grade I-IV, II-IV and III-IV acute GVHD were 42.0%, 34.0% and 12.0%, respectively. no significant difference on acute GVHD was observed between two ATG groups. Interestingly, with a cutoff point of 0.585×10 9 /L, low pre-ATG ALC group (18 patients) showed reduced CIs of grade I-IV (16.7% versus 56.3%, p=0.01), II-IV (16.7% versus 43.8%, p=0.07) and III-IV (0 versus 18.8%, p=0.05%) acute GVHD as compared to high ALC group (32 patients). The results suggested that this low-dose ATG/PTCy regimen was feasible and pre-ATG ALC levels could influence the occurrence of acute GVHD in this regimen.

Article activity feed